Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease

被引:360
作者
Kanellis, J
Kang, DH
机构
[1] Univ Melbourne, Dept Nephrol, Austin Hosp, Melbourne, Vic, Australia
[2] Univ Melbourne, Dept Med, Austin Hosp, Melbourne, Vic, Australia
[3] Ewha Womans Univ, Div Nephrol, Ewha Med Res Ctr, Seoul, South Korea
[4] Baylor Coll Med, Div Nephrol, Houston, TX 77030 USA
关键词
D O I
10.1016/j.semnephrol.2004.09.007
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Recent experimental findings have led to renewed interest in the possible role of uric acid in the pathogenesis of both hypertension and vascular disease. Often considered an antioxidant, biochemical and in vitro data indicate that noncrystalline, soluble uric acid also can react to form radicals, increase lipid oxidation, and induce various pro-oxidant effects in vascular cells. In vitro and in vivo findings suggest that uric acid may contribute to endothelial dysfunction by inducing antiproliferative effects on endothelium and impairing nitric oxide production. Proinflammatory and proliferative effects of soluble uric acid have been described on vascular smooth muscle cells (VSMCs), and in animal models of mild hyperuricemia, hypertension develops in association with intrarenal vascular disease. Possible adverse effects of uric acid on the vasculature have been linked to increased chemokine and cytokine expression, induction of the renin-angiotensin system, and to increased vascular C-reactive protein (CRP) expression. Experimental evidence suggests a complex but potentially direct causal role for uric acid in the pathogenesis of hypertension and atherosclerosis. © 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:39 / 42
页数:4
相关论文
共 42 条
[1]   Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein [J].
Abuja, PM .
FEBS LETTERS, 1999, 446 (2-3) :305-308
[2]   URIC-ACID PROVIDES AN ANTIOXIDANT DEFENSE IN HUMANS AGAINST OXIDANT-CAUSED AND RADICAL-CAUSED AGING AND CANCER - A HYPOTHESIS [J].
AMES, BN ;
CATHCART, R ;
SCHWIERS, E ;
HOCHSTEIN, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (11) :6858-6862
[3]   Uric acid and survival in chronic heart failure - Validation and application in metabolic, functional, and Hemodynamic staging [J].
Anker, SD ;
Doehner, W ;
Rauchhaus, M ;
Sharma, R ;
Francis, D ;
Knosalla, C ;
Davos, CH ;
Cicoira, M ;
Shamim, W ;
Kemp, M ;
Segal, R ;
Osterziel, KJ ;
Leyva, F ;
Hetzer, R ;
Ponikowski, P ;
Coats, AJS .
CIRCULATION, 2003, 107 (15) :1991-1997
[4]   When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid [J].
Bagnati, M ;
Perugini, C ;
Cau, C ;
Bordone, R ;
Albano, E ;
Bellomo, G .
BIOCHEMICAL JOURNAL, 1999, 340 :143-152
[5]   Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis [J].
Boring, L ;
Gosling, J ;
Cleary, M ;
Charo, IF .
NATURE, 1998, 394 (6696) :894-897
[6]   Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension [J].
Butler, R ;
Morris, AD ;
Belch, JJF ;
Hill, A ;
Struthers, AD .
HYPERTENSION, 2000, 35 (03) :746-751
[7]   Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy [J].
Cappola, TP ;
Kass, DA ;
Nelson, GS ;
Berger, RD ;
Rosas, GO ;
Kobeissi, ZA ;
Marbán, E ;
Hare, JM .
CIRCULATION, 2001, 104 (20) :2407-2411
[8]   Yin and Yang of uric acid in patients with stroke [J].
Chamorro, A ;
Planas, AM .
STROKE, 2004, 35 (01) :E11-E11
[9]   Antioxidant profile and early outcome in stroke patients [J].
Cherubini, A ;
Polidori, MC ;
Bregnocchi, M ;
Pezzuto, S ;
Cecchetti, R ;
Ingegni, T ;
di Iorio, A ;
Senin, U ;
Mecocci, P .
STROKE, 2000, 31 (10) :2295-2300
[10]  
COGHLAN JG, 1994, J THORAC CARDIOV SUR, V107, P248